FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2278570292> ?p ?o ?g. }

• W2278570292 endingPage "1005" @default.
• W2278570292 startingPage "997" @default.
• W2278570292 abstract "Vincristine sulfate liposome injection (VSLI; Marqibo®) is an encapsulated preparation of standard vincristine in sphingomyelin/cholesterol liposomes. Clinical trials in adults have demonstrated safety, tolerability, and activity, leading to Food and Drug Administration (FDA) approval for adults with relapsed acute lymphoblastic leukemia (ALL). Pediatric experience with VSLI is limited.This single center, phase I dose escalation study examined the safety, toxicity, maximum tolerated dose, and pharmacokinetics of VSLI administered weekly to pediatric patients age <21 years with relapsed or chemotherapy-refractory solid tumors or leukemia.Twenty-one subjects were treated in total. Median age was 13.3 years (range 2-19). Fourteen subjects completed one 28-day cycle of therapy and five subjects completed more than one cycle. No subject experienced dose-limiting toxicity (DLT) at the first dose level (1.75 mg/m(2) /dose, dose range: 2-3.7 mg). At the second dose level (2.25 mg/m(2) /dose, dose range: 1.3-4.5 mg), one subject had transient dose-limiting grade 4 transaminase elevation, and this dose level was expanded with no additional DLT observed. The second dose level then opened to an expansion phase to evaluate activity in ALL. Clinical activity included minimal residual disease negative complete remission in one subject with ALL and stable disease in nine subjects. Clearance of total vincristine was found to be approximately 100-fold lower in comparison to published data using standard vincristine.Children tolerate 2.25 mg/m(2) /dose of weekly VSLI (the adult FDA-approved dose) with evidence for clinical activity without dose-limiting neurotoxicity. Future plans include studying VSLI as substitution for standard vincristine with combination chemotherapy in children with ALL." @default.
• W2278570292 created "2016-06-24" @default.
• W2278570292 creator A5009042526 @default.
• W2278570292 creator A5013821837 @default.
• W2278570292 creator A5030044268 @default.
• W2278570292 creator A5047300808 @default.
• W2278570292 creator A5052568161 @default.
• W2278570292 creator A5059502763 @default.
• W2278570292 creator A5071679104 @default.
• W2278570292 creator A5075130859 @default.
• W2278570292 creator A5083416957 @default.
• W2278570292 date "2016-02-17" @default.
• W2278570292 modified "2023-09-26" @default.
• W2278570292 title "Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias" @default.
• W2278570292 cites W1532844849 @default.
• W2278570292 cites W155388932 @default.
• W2278570292 cites W1559459501 @default.
• W2278570292 cites W1679600454 @default.
• W2278570292 cites W1822941578 @default.
• W2278570292 cites W1976015864 @default.
• W2278570292 cites W1981814833 @default.
• W2278570292 cites W1992656294 @default.
• W2278570292 cites W1994226708 @default.
• W2278570292 cites W1998183719 @default.
• W2278570292 cites W2017225733 @default.
• W2278570292 cites W2019607817 @default.
• W2278570292 cites W2055402663 @default.
• W2278570292 cites W2065825204 @default.
• W2278570292 cites W2068155954 @default.
• W2278570292 cites W2078628247 @default.
• W2278570292 cites W2094818544 @default.
• W2278570292 cites W2102349540 @default.
• W2278570292 cites W2104438003 @default.
• W2278570292 cites W2128628566 @default.
• W2278570292 cites W2133201432 @default.
• W2278570292 cites W2136627573 @default.
• W2278570292 cites W2137365058 @default.
• W2278570292 cites W2150932917 @default.
• W2278570292 cites W2159507916 @default.
• W2278570292 cites W2261972677 @default.
• W2278570292 cites W4230692940 @default.
• W2278570292 cites W4376595466 @default.
• W2278570292 doi "https://doi.org/10.1002/pbc.25937" @default.
• W2278570292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6689398" @default.
• W2278570292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26891067" @default.
• W2278570292 hasPublicationYear "2016" @default.
• W2278570292 type Work @default.
• W2278570292 sameAs 2278570292 @default.
• W2278570292 citedByCount "50" @default.
• W2278570292 countsByYear W22785702922016 @default.
• W2278570292 countsByYear W22785702922017 @default.
• W2278570292 countsByYear W22785702922018 @default.
• W2278570292 countsByYear W22785702922019 @default.
• W2278570292 countsByYear W22785702922020 @default.
• W2278570292 countsByYear W22785702922021 @default.
• W2278570292 countsByYear W22785702922022 @default.
• W2278570292 countsByYear W22785702922023 @default.
• W2278570292 crossrefType "journal-article" @default.
• W2278570292 hasAuthorship W2278570292A5009042526 @default.
• W2278570292 hasAuthorship W2278570292A5013821837 @default.
• W2278570292 hasAuthorship W2278570292A5030044268 @default.
• W2278570292 hasAuthorship W2278570292A5047300808 @default.
• W2278570292 hasAuthorship W2278570292A5052568161 @default.
• W2278570292 hasAuthorship W2278570292A5059502763 @default.
• W2278570292 hasAuthorship W2278570292A5071679104 @default.
• W2278570292 hasAuthorship W2278570292A5075130859 @default.
• W2278570292 hasAuthorship W2278570292A5083416957 @default.
• W2278570292 hasBestOaLocation W22785702922 @default.
• W2278570292 hasConcept C112705442 @default.
• W2278570292 hasConcept C121332964 @default.
• W2278570292 hasConcept C126322002 @default.
• W2278570292 hasConcept C142424586 @default.
• W2278570292 hasConcept C197934379 @default.
• W2278570292 hasConcept C2776694085 @default.
• W2278570292 hasConcept C2776755627 @default.
• W2278570292 hasConcept C2777288759 @default.
• W2278570292 hasConcept C2778375690 @default.
• W2278570292 hasConcept C2779429289 @default.
• W2278570292 hasConcept C29730261 @default.
• W2278570292 hasConcept C31760486 @default.
• W2278570292 hasConcept C71924100 @default.
• W2278570292 hasConcept C87355193 @default.
• W2278570292 hasConcept C90924648 @default.
• W2278570292 hasConcept C98274493 @default.
• W2278570292 hasConceptScore W2278570292C112705442 @default.
• W2278570292 hasConceptScore W2278570292C121332964 @default.
• W2278570292 hasConceptScore W2278570292C126322002 @default.
• W2278570292 hasConceptScore W2278570292C142424586 @default.
• W2278570292 hasConceptScore W2278570292C197934379 @default.
• W2278570292 hasConceptScore W2278570292C2776694085 @default.
• W2278570292 hasConceptScore W2278570292C2776755627 @default.
• W2278570292 hasConceptScore W2278570292C2777288759 @default.
• W2278570292 hasConceptScore W2278570292C2778375690 @default.
• W2278570292 hasConceptScore W2278570292C2779429289 @default.
• W2278570292 hasConceptScore W2278570292C29730261 @default.
• W2278570292 hasConceptScore W2278570292C31760486 @default.
• W2278570292 hasConceptScore W2278570292C71924100 @default.
• W2278570292 hasConceptScore W2278570292C87355193 @default.

• next